Quick Answer
Precision medicine is an approach to healthcare that customises prevention, diagnosis, and treatment to each individual's unique genetic makeup, environment, microbiome, and lifestyle — rather than applying population-average protocols. The term was popularised by the 2015 US Precision Medicine Initiative (now All of Us Research Program), which aimed to recruit 1 million participants for long-term health research. Also called personalised medicine, stratified medicine, or P4 medicine (predictive, preventive, personalised, participatory).
Traditional medicine operates on a “one size fits most” paradigm: when two patients present with the same diagnosis, they receive the same first-line treatment. This is not negligence — it reflects the practical limits of what clinicians historically could measure and the statistical logic of population-level randomised controlled trials. A drug that works for 60% of people in a trial is approved for everyone with that condition, even though the remaining 40% derive no benefit and may experience harm. For many acute conditions, this approach is perfectly adequate. For chronic disease, cancer, and complex metabolic disorders, it frequently is not.
Precision medicine segments patients by biological subtype, genetic profile, or measurable biomarker signature to select the most effective intervention for that specific individual. The clearest illustration is breast cancer: two women may both receive a diagnosis of “stage II breast cancer,” but one has HER2-positive disease responding to trastuzumab while the other has triple-negative disease requiring a different chemotherapy protocol entirely. Treating both identically — as traditional oncology once did — would mean under-treating one and over-treating the other. Precision oncology identifies which patient has which subtype before the first dose is given.
The shift is not merely technological — it is conceptual. Traditional medicine asks “what is the best treatment for this disease?” Precision medicine asks “what is the best treatment for this patient with this disease, given their biology, environment, and history?” That reframing has consequences for drug development, clinical trial design, reimbursement models, and the doctor-patient relationship. Learn more about what precision medicine is changing about healthcare.
Genomics is the most widely discussed pillar of precision medicine. Genome-wide association studies (GWAS) have now identified hundreds of thousands of single nucleotide polymorphisms (SNPs) associated with disease risk. Polygenic risk scores (PRS) aggregate thousands of these small-effect variants into a composite risk estimate that can stratify populations more accurately than any single gene test. For coronary artery disease, high-risk PRS individuals have a lifetime risk comparable to carriers of a single rare monogenic mutation — yet the polygenic risk is present in far more people and is largely undetected by standard clinical genetics. A PRS for cardiovascular disease outperforms LDL cholesterol alone in predicting first MI in some populations.
Pharmacogenomics examines how inherited genetic variants affect the way your body metabolises and responds to drugs. Epigenomics studies chemical modifications to DNA — particularly methylation patterns — that alter gene expression without changing the DNA sequence itself. These epigenetic marks are influenced by diet, stress, toxin exposure, and sleep, making them a bridge between genetics and lifestyle. Proteomics profiles the full complement of proteins your cells express, and metabolomics characterises the small molecules (metabolites) produced by cellular processes. Each “omic” layer reveals a different facet of biology. Learn more about how your gut microbiome informs personalised medicine.
Multi-omics integration — combining two or more of these data layers simultaneously — is where the most powerful insights emerge. A 2019 Stanford study by Michael Snyder's group followed 109 individuals with dense multi-omic profiling over years, detecting pre-diabetic insulin resistance, cardiovascular risk signals, and Lyme disease infection before clinical presentation. The microbiome, now recognised as a quasi-organ with over 100 trillion microbial cells carrying 150 times more genes than the human genome, interacts with every omic layer — modulating immune response, drug metabolism, neurological signalling, and metabolic function in ways that single-analyte tests cannot capture.
Pharmacogenomics is arguably the most immediately actionable area of precision medicine for the average patient. An estimated 95% of people carry at least one clinically actionable pharmacogenomic variant, yet most are never tested. The clinical consequences range from mild (suboptimal dosing requiring adjustment) to severe (life-threatening adverse drug reactions from a drug that would have been avoided with prior testing). The FDA now includes pharmacogenomic information in the prescribing labels of more than 200 drugs — making PGx testing a recognised part of evidence-based prescribing rather than an experimental curiosity.
The most studied variants are in the cytochrome P450 enzyme family. CYP2D6 metabolises approximately 25% of all commonly prescribed drugs, including codeine (poor metabolisers get no analgesic effect; ultra-rapid metabolisers can experience opioid toxicity), tamoxifen (the active metabolite endoxifen requires CYP2D6; poor metabolisers may have worse breast cancer outcomes), and many antidepressants including paroxetine, fluoxetine, and venlafaxine. CYP2C19 determines clopidogrel (Plavix) activation — poor metabolisers derive essentially no antiplatelet benefit from the standard dose, dramatically increasing cardiovascular risk after stent placement. This is now a black box warning in the FDA label. CYP2C19 also affects PPI metabolism, SSRI efficacy, and several antifungals.
Beyond CYP enzymes, HLA-B*5701 testing before abacavir prescription (an HIV antiretroviral) has essentially eliminated severe hypersensitivity reactions — a pharmacogenomics success story where prospective testing became standard of care. The VKORC1 and CYP2C9 gene variants together explain approximately 50% of inter-individual variation in warfarin dose requirements, contributing to it being one of the most common causes of preventable serious drug adverse events when dosing is not personalised. For a deep dive into pharmacogenomics explained in depth, including how to order testing, see our detailed guide.
Cancer is where precision medicine has delivered its most dramatic and well-documented clinical wins. The reason is biological: cancer is fundamentally a disease of genomic dysregulation, and each tumour accumulates a unique set of somatic mutations that drive its growth. Next-generation sequencing of tumour biopsies (tumour profiling) can now identify hundreds of driver mutations, copy number alterations, gene fusions, and microsatellite instability status simultaneously, and match them against a growing catalogue of approved targeted therapies and active clinical trials. Platforms like Foundation Medicine FoundationOne CDx, Tempus xT, and Caris Molecular Intelligence have made comprehensive tumour profiling clinically available across solid tumours.
The magnitude of the benefit in matched targeted therapy can be striking. Pembrolizumab (Keytruda), an anti-PD-1 immunotherapy, produces objective response rates of approximately 45% in non-small cell lung cancer patients with PD-L1 tumour proportion score of 50% or higher — compared to roughly 10% in unselected NSCLC populations. BRCA1/2 mutations in ovarian and breast cancer predict sensitivity to PARP inhibitors (olaparib, niraparib), drugs that exploit synthetic lethality to kill cancer cells that cannot repair double-strand DNA breaks. EGFR-mutated NSCLC responds to osimertinib. BCR-ABL1 fusion-positive CML responds to imatinib (Gleevec). These are not incremental improvements — they are transformations in survival curves that would be invisible without molecular stratification. For a thorough look at precision oncology and tumour profiling, our blog covers the current landscape.
Liquid biopsy represents the frontier of precision oncology: detecting tumour-derived DNA fragments (ctDNA) in a blood draw rather than a surgical biopsy. Grail's Galleri test screens for 50+ cancer types simultaneously from a blood sample, with a specificity of 99.5%, and is currently in large NHS validation trials (the NHS-Galleri study, 140,000 participants). Early detection studies suggest ctDNA signals can appear 1–4 years before conventional imaging diagnosis. Minimal residual disease (MRD) monitoring via liquid biopsy is already standard in certain haematological malignancies, predicting relapse months before clinical symptoms return.
Access to precision medicine has democratised substantially over the past decade. Consumer-grade genetic testing through 23andMe (approximately $99–$229 depending on kit) or AncestryDNA provides a low-cost entry point covering 700,000+ SNPs, including some health predisposition reports and carrier status for monogenic conditions. These tests are not clinical-grade — they use array genotyping rather than sequencing — but raw data can be uploaded to third-party interpretation tools or re-analysed as sequencing costs fall. For clinical-grade sequencing with physician interpretation, Invitae and GeneDx offer targeted gene panels, exome sequencing, and whole genome sequencing ordered through healthcare providers, typically ranging from $250 to $2,500 depending on panel scope and indication.
Pharmacogenomic testing has the clearest near-term clinical utility for most adults. GeneSight and Genomind specialise in psychiatric pharmacogenomics — providing actionable guidance on antidepressant, antipsychotic, and ADHD medication selection and dosing based on CYP2D6, CYP2C19, CYP3A4, SLC6A4, MTHFR, and other variants. These panels cost $200–$500 and are increasingly covered by insurance when ordered by a physician following inadequate medication response. Microbiome profiling services (Viome at $179–$349, Ombre, DayTwo for metabolic phenotyping) analyse stool samples to characterise gut bacterial composition and functional activity, providing dietary and supplement recommendations aimed at metabolic health, inflammation, and energy.
When to see a genetic counsellor: if you have a strong family history of cancer (particularly breast, ovarian, colorectal, or pancreatic), a personal cancer diagnosis, a rare disease without clear diagnosis, or a positive consumer genetics result flagging a high-risk variant (BRCA1/2, APC, Lynch syndrome genes), a board-certified genetic counsellor (CGC) is the appropriate next step. They can order CLIA-certified confirmatory testing, contextualise your results within your family history, and coordinate cascade testing for relatives. Platforms like QuanMed AI are building the infrastructure to aggregate multi-omic data — genetics, labs, wearables, microbiome — into a unified health picture that clinicians and patients can navigate together.
Artificial intelligence is the engine that will make precision medicine scalable. The bottleneck in precision medicine is not data collection — it is interpretation. Radiomics algorithms can extract hundreds of quantitative features from a single CT scan that are invisible to the human eye, predicting tumour biology, treatment response, and recurrence risk without a biopsy. DeepMind's AlphaFold solved the protein structure prediction problem that had stymied structural biology for 50 years — opening a new era of rational drug design targeting proteins that were previously “undruggable” because their 3D shape was unknown. In clinical trial design, AI is enabling adaptive platform trials that continuously reassign patients to the arms most likely to benefit them, cutting the time and cost of drug development.
Continuous physiological monitoring is shifting the data model from annual snapshot to real-time stream. Continuous glucose monitors (CGMs), originally developed for type 1 diabetics, are now used by metabolically healthy individuals and athletes to understand glycaemic variability — a metric that standard HbA1c completely obscures. The Levels Health study showed that nearly 50% of non-diabetic CGM users show post-meal glucose excursions above 140 mg/dL (a pre-diabetic threshold), suggesting that “normal” fasting glucose masks meaningful metabolic dysfunction in a large fraction of the population. Wearable ECG patches (Zio by iRhythm), implantable loop recorders, and consumer smartwatch ECG algorithms have transformed arrhythmia detection. Next-generation biosensors are in development for continuous cortisol, lactate, and inflammatory marker monitoring in sweat and interstitial fluid.
The foundational data infrastructure for precision medicine at population scale is being built now. The NIH's All of Us Research Program has enrolled over 700,000 participants (as of 2025) with linked electronic health records, genomic sequencing, wearable data, and longitudinal surveys — the largest precision medicine cohort in the US. The UK Biobank holds deep phenotypic and genomic data on 500,000 British participants and has enabled over 7,000 peer-reviewed publications. Federated learning — where AI models are trained across distributed datasets without raw data ever leaving institutional servers — is solving the privacy and data governance challenges that have slowed multi-institutional research. The convergence of these trends (AI, continuous monitoring, federated research, consumer genomics) points toward a near future where precision medicine principles reach primary care within the next 5–10 years, not only specialist oncology departments.
Free Tool
Find out how much precision medicine applies to your situation — including whether genetic testing, pharmacogenomics, or microbiome analysis would meaningfully change your health management.
Open Tool →The terms are often used interchangeably, but there is a subtle distinction. “Personalised medicine” emphasises tailoring treatment to an individual. “Precision medicine” is slightly broader — it can mean stratifying patients into subgroups (e.g. by gene variant or tumour biomarker) even when those subgroups contain many individuals. The US National Academies preferred “precision medicine” specifically to avoid the implication that each patient gets a completely unique treatment, which is not always practical.
Costs vary widely by type of testing. Whole genome sequencing now costs $200–$500 through DTC services. Clinical-grade whole exome or genome sequencing through a lab ranges from $500–$3,000. Pharmacogenomic panels cost $200–$500 and are increasingly covered by insurance when clinically indicated. Cancer tumour profiling (Foundation Medicine, Tempus, Caris) typically costs $3,000–$7,000 but is often covered by insurance for oncology patients. Consumer-level precision medicine entry points (23andMe, Viome) start under $200.
Cancer patients currently see the clearest benefits — tumour profiling is changing treatment decisions and improving outcomes in multiple cancer types. Patients on medications with known pharmacogenomic interactions (certain antidepressants, blood thinners, cardiac drugs) benefit from pharmacogenomic testing. People with rare genetic diseases benefit from diagnostic odyssey-ending gene sequencing. Increasingly, healthy adults interested in disease prevention are using precision medicine approaches for early risk stratification.
Coverage varies significantly by country, insurer, and indication. In the US, pharmacogenomic testing is covered by many insurers when ordered by a physician for specific conditions (certain psychiatric medications, cardiology). Tumour genomic profiling is covered by Medicare and many private insurers for advanced cancer. Consumer genetic testing (23andMe) is typically not covered. In the UK, NHS Genomic Medicine Service covers clinical genomic testing for specific conditions. Coverage is expanding as clinical utility evidence grows.
Genetic testing is one component of precision medicine. Precision medicine integrates genetic data with many other data types: biomarkers from blood tests, microbiome profiling, continuous physiological monitoring (wearables, CGMs), environmental exposures, and medical history. A genetic test tells you about inherited risk and pharmacogenomics. Precision medicine uses all available biological data to make real-time clinical decisions about prevention, diagnosis, and treatment.
Yes — preventive precision medicine is an active and growing area. Polygenic risk scores can identify high-risk individuals who would benefit from earlier or more aggressive cardiovascular screening. Pharmacogenomics can prevent adverse drug reactions before they occur. Continuous glucose monitoring identifies metabolic dysfunction before diagnosis. Cancer liquid biopsies (like Grail's Galleri test) aim to detect 50+ cancer types at early stages. The vision is to shift from reactive to proactive healthcare guided by individual biological data.
© 2026 QuanMed - All rights reserved